Carl Lindgren
Chairman of the Board since 2024. Board member since 2023. Born 1968.
More than 25 years of experience in senior commercial positions within the Life Science industry, including roles at AstraZeneca, Lundbeck, Karo Healthcare, and EQL Pharma.
Education: B.Sc., Business Administration and Economics, Lund University
Other assignments: Board member BioMedica AB, Chief Business Development Officer at EQL Pharma
Holding: 40,000 shares
Independent in relation to the Company’s major shareholders and the Company and management.
Mats Johansson
Chairman of the Board 2013-2020. Board member 2021. Born 1961.
Over 30 years of experience in founding and long-term development of companies, as well as listing companies on Nasdaq Stockholm.
Education: High School
Other assignments: Chairman of the Board, Abraxas Holding AB, Easy Depot AB, Volubus AB, and SiB Solutions AB. Board member, Klarabo Sverige AB, Nudging Capital AB.
Holding: 1 250,725 shares
Dependent in relation to the Company’s major shareholders and the Company and management.
Orest Lastow
Board member since 2013. Born 1964.
Over 30 years of experience in inhaled pharmaceuticals, has invented around 30 inhalers, including all of Iconovo’s inhalation platforms. Author of over 50 patent applications and several research articles and books.
Education: MSc, Engineering Physics, Lund University. PhD, Aerosol Physics, Brunel University, London.
Other assignments: Board member, Lastow Consulting AB.
Holding: 826,400 shares
Dependent in relation to the Company’s major shareholders and the Company and management.
Berndt Axelsson
Board member since 2013. Born 1959.
20-year background in PwC as a management consultant. Has since worked in the industry as CFO and CEO with a focus on M&A, Legal & Risk, and international distribution.
Education: BA Economics, Växjö University
Other assignments: CEO and Board member, BAN Business Consulting AB. Chairman of the Board, INVID Jönköping AB, Nässjö Näringsliv AB.
Holding: 320,000 shares
Independent in relation to the Company’s major shareholders and the Company and management.
Agneta Walhagen
Board member since 2019. Born 1960.
Has extensive experience in R&D within the pharmaceutical industry, focusing on inhalation and inflammatory diseases in the lung and skin.
Education: PhD, Analytical Science, Lund university.
Other assignments: Independent Consultant.
Holding: 4,500 shares
Independent in relation to the Company’s major shareholders and the Company and management.
Erik Ekman
Board member since 2024. Born 1972.
Over 20 years’ experience from the pharmaceutical Industry, including Production (e.g. Turbuhaler), Global Operations, IT, Consultancy and General management. Prior to Bluefish Pharmaceuticals, Erik was associated with AstraZeneca, Cambrex and CapGemini Ernst & Young.
Education: M.Sc., Industrial Engineering and Management, Linköping University
Other assignments: CEO at Bluefish Pharmaceuticals
Holding: 0 shares
Dependent in relation to the Company’s major shareholders and the Company and management.